Kipps T J
Department of Medicine, University of California San Diego, La Jolla 92093-0663, USA.
Curr Opin Hematol. 1998 Jul;5(4):244-53. doi: 10.1097/00062752-199807000-00003.
Recent studies have improved our understanding of the cytogenesis, biology, and therapy of chronic lymphocytic leukemia (CLL). This review highlights this recent progress reported over the past year. We have improved our understanding of the cytogenetic abnormalities in CLL and soon may see identification of new tumor suppressor genes that may be deleted in the leukemia cells of a large number of patients with this disease. We have achieved a better understanding of the surface antigens that help govern the pattern of tissue-infiltration of leukemia cells in vivo. Studies on the immune pathophysiology of CLL are providing clues to potential mechanisms leading to the immunodeficiency associated with this disease. Combination chemotherapy with purine analogues is showing promise for improved efficacy in CLL. Finally, new therapies incorporating bone marrow transplantation, and possibly gene therapy, increasingly are being considered for the therapy of patients with this disease.
近期的研究增进了我们对慢性淋巴细胞白血病（CLL）细胞发生、生物学特性及治疗方法的理解。本综述着重介绍了过去一年间所报道的这一最新进展。我们对CLL中的细胞遗传学异常有了更深入的认识，并且很快可能会发现新的肿瘤抑制基因，这些基因可能在大量该疾病患者的白血病细胞中缺失。我们对有助于控制白血病细胞在体内组织浸润模式的表面抗原有了更好的理解。对CLL免疫病理生理学的研究为导致与该疾病相关的免疫缺陷的潜在机制提供了线索。嘌呤类似物联合化疗在改善CLL疗效方面显示出前景。最后，越来越多的人开始考虑采用包括骨髓移植以及可能的基因治疗在内的新疗法来治疗该疾病的患者。
